Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 8 Publications

7 Customer Reviews

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

  • (a) Westernblot analysis of the whole cell lysate from WT-MTEC, KO-MTEC and 1601 treated with or without Nutlin-3a (15 μM for MTEC) with antibodies as indicated.

    Int J Cancer. 2019, 144(4):777-787. Nutlin-3a purchased from Selleck.

    Protein expression of p53, TAZ and CYP24A1 were detected by western blot after treatment with Nutlin 3a in CCLP-1.

    Cancer Lett, 2016, 381(2):370-9. Nutlin-3a purchased from Selleck.

  • Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

    C) Control-threated cells show an strong nuclear expression of MDM2 and predominantly cytoplasmic localization of FOXM1. D) After treatment with nutlin-3a, the MDM2 immunoreactivity shifted to the perinuclear space indicating a de novo 952 MDM2 synthesis as result of increased p53 activity. In those cells, FOXM1 expression is lost due to p53 activation.

    Neuroendocrinology, 2018, 107(1):1-23. Nutlin-3a purchased from Selleck.

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NUS2S|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwNkGyN|ch|ryP NEXzeFBUSU6JRWK=
H4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITx[YlKSzVyPUCuOlYzQCEQvF2= NFn2SpRUSU6JRWK=
PA-1 NIHVNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILyVnRKSzVyPUCuPFcxQTZizszN NYPzc4dDW0GQR1XS
NKM-1 M2nRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHRNoMzUUN3ME2xMlA1QTNzIN88US=> MVXTRW5ITVJ?
NEC8 NUP6dWVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TqNGlEPTB;MT6yNVU4OiEQvF2= MYnTRW5ITVJ?
EoL-1-cell Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\TeGlEPTB;MT6yOlcxOSEQvF2= MXHTRW5ITVJ?
K5 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Md|B3UUN3ME2xMlQzODd{IN88US=> NVHJ[XJHW0GQR1XS
QIMR-WIL NVfjeJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzlPGNKSzVyPUGuOlA5PTRizszN M4n3XHNCVkeHUh?=
MOLT-16 NIjs[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17ZbWlEPTB;MT63PFYxPCEQvF2= M3LiWHNCVkeHUh?=
CHP-212 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;6WGlEPTB;MT64NVM3QSEQvF2= NFnWS2tUSU6JRWK=
CTB-1 NFTjWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLM[YxKSzVyPUKuNFIzPDZizszN MkPwV2FPT0WU
MOLT-4 NWf2OZRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSwUYJsUUN3ME2yMlMzQDV|IN88US=> M2juZXNCVkeHUh?=
A101D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTiTWM2OD1{LkO1NFEh|ryP NEnPe3RUSU6JRWK=
DOHH-2 NX:w[IRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrTbJlKSzVyPUKuOFIzPzlizszN NGnUO3ZUSU6JRWK=
ES4 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQeVlKSzVyPUKuOFMyPTVizszN NGrvbnlUSU6JRWK=
SW780 NFzBfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwNUC4PFMh|ryP M33VVHNCVkeHUh?=
VA-ES-BJ NF7EPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TjRWlEPTB;Mj61OFEyKM7:TR?= MWDTRW5ITVJ?
RPMI-8866 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnzSIdKSzVyPUKuOVYzOTRizszN M{jJPXNCVkeHUh?=
ML-2 M1Hmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLwTWM2OD1{LkW2OVc3KM7:TR?= NXPiPZFuW0GQR1XS
MSTO-211H MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjTTWM2OD1{LkW3OFUyKM7:TR?= M122WHNCVkeHUh?=
JVM-3 NHGxbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7GTWM2OD1{LkW5N|I1KM7:TR?= MlHEV2FPT0WU
A3-KAW NXi3OFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwNkG4NVgh|ryP NG\zXmJUSU6JRWK=
DK-MG NX3Rc|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HxPGlEPTB;Mj62NlQ4OSEQvF2= NIPQcphUSU6JRWK=
LNCaP-Clone-FGC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P6TWlEPTB;Mj62OFMyQCEQvF2= Mlq3V2FPT0WU
HT-144 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fzUGlEPTB;Mj62OFU4PyEQvF2= NEXNRWtUSU6JRWK=
NB69 NVr5VZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwNkWzN|Qh|ryP NUTQbXF3W0GQR1XS
A172 NH7sc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OzNmlEPTB;Mj62O|U5QCEQvF2= M17SVXNCVkeHUh?=
RS4-11 M3PMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwN{K0NFch|ryP NFmxdXpUSU6JRWK=
DU-4475 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjHTWM2OD1{Lke5OVAzKM7:TR?= NVX4NmZtW0GQR1XS
SJSA-1 M4n4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH5bph3UUN3ME2yMlgzPTV4IN88US=> NUDDbWUyW0GQR1XS
BV-173 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxTWM2OD1{Lki0OFM6KM7:TR?= Mlz5V2FPT0WU
U-2-OS M1vxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HaUGlEPTB;Mj65NVA4KM7:TR?= M3P6UXNCVkeHUh?=
CHP-134 NETSblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe5O28{UUN3ME2yMlk{QDh{IN88US=> MXvTRW5ITVJ?
D-502MG M3z4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vjcmlEPTB;Mj65O|E2PCEQvF2= MlLRV2FPT0WU
KS-1 NVrnRm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwMEG2NlMh|ryP NXnBV3FSW0GQR1XS
A204 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNwMEW1PFgh|ryP MVzTRW5ITVJ?
KGN M2DWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPy[mpMUUN3ME2zMlA5PDl4IN88US=> MXTTRW5ITVJ?
NCI-H292 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMUKwNlgh|ryP M2HZVXNCVkeHUh?=
CAKI-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf3TWM2OD1|LkGyOlk1KM7:TR?= MUfTRW5ITVJ?
C2BBe1 NHnMTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET6W5ZKSzVyPUOuNVcxOjZizszN M3jwS3NCVkeHUh?=
NB10 M3XIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNTWM2OD1|LkKwPVY3KM7:TR?= MYfTRW5ITVJ?
MHH-NB-11 M1vxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7wTWM2OD1|LkK2PFI4KM7:TR?= MWTTRW5ITVJ?
NCI-SNU-1 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK2TWM2OD1|LkK3PFQ{KM7:TR?= NFS4SY9USU6JRWK=
HCT-116 NEL1Om1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzVR4lKSzVyPUOuN|A{OzVizszN MnnKV2FPT0WU
G-401 NF3xS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH4OXdvUUN3ME2zMlM3OzJ{IN88US=> MU\TRW5ITVJ?
MN-60 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nXSWlEPTB;Mz60OFA6OiEQvF2= NIC2[lhUSU6JRWK=
SW982 NXTKR5dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnZe3RKSzVyPUOuOVA5PDhizszN NUC2VZF6W0GQR1XS
RKO M{jq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nXb2lEPTB;Mz61N|k{PiEQvF2= NIC0Z5JUSU6JRWK=
D-283MED NXzEVos1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfBbndlUUN3ME2zMlU4QTh4IN88US=> NHrPXGZUSU6JRWK=
LB996-RCC NGPqdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG3NJBKSzVyPUOuOlI2PThizszN MYLTRW5ITVJ?
A549 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfZdYlKSzVyPUOuOlM2PTJizszN MXvTRW5ITVJ?
LB2241-RCC M3;TXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwNkW3NFgh|ryP NGLEeG9USU6JRWK=
SK-HEP-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLGOZlKSzVyPUOuO|QzQTdizszN MWXTRW5ITVJ?
G-402 M{K4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DxeGlEPTB;Mz64NFg{OiEQvF2= M{iwRXNCVkeHUh?=
GOTO MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfXbXRKSzVyPUOuPFQ{OzNizszN NV34eYJyW0GQR1XS
LOXIMVI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTNwOEW2O|Uh|ryP MlHJV2FPT0WU
NH-12 NX3TZXJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXziN453UUN3ME20MlAyQTV7IN88US=> NUH2R5piW0GQR1XS
CTV-1 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PEOWlEPTB;ND6wO|k4OyEQvF2= NIP0RXFUSU6JRWK=
CP50-MEL-B MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj5Ond3UUN3ME20MlI1Ozl{IN88US=> MWDTRW5ITVJ?
RH-18 NVzQNYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDVTWM2OD12LkK3O|A3KM7:TR?= NEXwcnhUSU6JRWK=
NB17 NG\ZcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT5d4xKSzVyPUSuN|E4PjhizszN MYrTRW5ITVJ?
A375 NXXGe|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3CTXBmUUN3ME20MlM{PTJ2IN88US=> M4jxUnNCVkeHUh?=
IST-MES1 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;RdWlEPTB;ND60NVQyOSEQvF2= Mlm1V2FPT0WU
MZ2-MEL M{nmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHOW5FoUUN3ME20MlUxOTV3IN88US=> Mn21V2FPT0WU
CAL-54 MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6yTWM2OD12LkWzNFE6KM7:TR?= NF7vdW9USU6JRWK=
NCI-H28 M2XZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TjeWlEPTB;ND62NlcyPyEQvF2= M1fsdHNCVkeHUh?=
D-247MG M2rYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLMTWM2OD12Lke1NFczKM7:TR?= Mn;EV2FPT0WU
NCI-H460 NEX5[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nZRmlEPTB;ND65NVEzPyEQvF2= NXe0VZRHW0GQR1XS
MCF7 NIPpWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PENWlEPTB;NT60OFI1PCEQvF2= MXrTRW5ITVJ?
697 NYPyRppyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;sZWlEPTB;NT60OFU2KM7:TR?= MlXZV2FPT0WU
ONS-76 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XHVmlEPTB;NT61O|AxQSEQvF2= M1vCVXNCVkeHUh?=
C32 NGTBdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGwVJFKSzVyPUWuOlAxOjlizszN MVPTRW5ITVJ?
OS-RC-2 NGXvdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LZSGlEPTB;NT63N|g5PyEQvF2= NVT0NWd1W0GQR1XS
MEL-HO NFPiSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHHTWM2OD13Lki1OlY4KM7:TR?= MnP1V2FPT0WU
LoVo MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZwMEG2NlQh|ryP Mo\5V2FPT0WU
AGS NHz2bpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfvdoVKSzVyPU[uNVQ5OjhizszN NFvlSlZUSU6JRWK=
GI-ME-N NEPHSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD14LkKyOFIyKM7:TR?= NWO0R2FTW0GQR1XS
H-EMC-SS M3:xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3jTWM2OD14LkO4OkDPxE1? NIf6NlhUSU6JRWK=
RVH-421 NEXQOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zKdGlEPTB;Nj60NlQzQCEQvF2= MVLTRW5ITVJ?
SW954 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXlOYZKSzVyPU[uOVU2PzJizszN MWLTRW5ITVJ?
NB5 M4rOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[3dYlYUUN3ME22MlU3OTh|IN88US=> NUL4N3p1W0GQR1XS
NCI-H2122 NEfxemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLrUoRKSzVyPU[uOVg4QTNizszN NI\JNFFUSU6JRWK=
AM-38 NVvn[pRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\vZlBoUUN3ME22Mlc2PjN7IN88US=> M4C4VnNCVkeHUh?=
KNS-81-FD MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi5OFNKSzVyPU[uO|Y1QTRizszN M3rmb3NCVkeHUh?=
LS-513 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD14Lke5NFI3KM7:TR?= MUPTRW5ITVJ?
A427 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnwTWM2OD14Lki3PFI6KM7:TR?= NXLj[mdqW0GQR1XS
WM-115 M3rjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZwOUOyN{DPxE1? NGHQe3BUSU6JRWK=
COLO-829 NH\rTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfWTFJzUUN3ME23MlI1OTh6IN88US=> NIPYb3hUSU6JRWK=
NCI-H1650 NGn4e5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC3Om9UUUN3ME23MlM6OjJ6IN88US=> NWXmOGhvW0GQR1XS
NCI-H358 NV;4c3lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDvTWM2OD15LkS0PFc6KM7:TR?= NV3LbWdUW0GQR1XS
HT-1080 NGW5fI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHoTWM2OD15LkS4NlU1KM7:TR?= NGftZnRUSU6JRWK=
HCC2218 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTdwNkK5O{DPxE1? NYrrSVJ7W0GQR1XS
NCI-H661 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTaeXVKSzVyPUeuPFcxPjlizszN MkHmV2FPT0WU
KM-H2 M{PQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3UTWM2OD15Lki4Olk1KM7:TR?= NX7CTIJkW0GQR1XS
RPMI-2650 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ToW2lEPTB;Nz65OFQyPCEQvF2= M2LtR3NCVkeHUh?=
NCI-H226 NVLPSmtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjoTlAxUUN3ME24MlIyOTJ{IN88US=> MULTRW5ITVJ?
MKN45 M3nGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf0V|VKSzVyPUiuNlY3ODJizszN MXrTRW5ITVJ?
D-392MG NVnaSWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLaTWM2OD16LkWyO|IzKM7:TR?= MXXTRW5ITVJ?
RCC10RGB NUm0cGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjQ[JZKSzVyPUiuPFY3QTVizszN M4H6WnNCVkeHUh?=
CAL-51 NHP0b5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NViyT2dkUUN3ME25MlExOjVzIN88US=> MmWxV2FPT0WU
COLO-678 NUHne3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5SWlEPTB;OT6zNlgyOSEQvF2= NFe4V3BUSU6JRWK=
SK-MEL-24 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTlwNUW4OVYh|ryP M3ftOXNCVkeHUh?=
SK-MEL-30 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTtTWM2OD17Lkm0OFc3KM7:TR?= MnmxV2FPT0WU
MMAC-SF NFHH[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHqTWM2OD1zMD6zPVYyKM7:TR?= NUS0[3d4W0GQR1XS
NTERA-S-cl-D1 NYLsfZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC5Xo9KSzVyPUGwMlY2ODhizszN NHTlVpFUSU6JRWK=
NB12 M1zN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFzLkWwN{DPxE1? M13KPXNCVkeHUh?=
UACC-257 M2Dqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e3dWlEPTB;MUGuPFY6PSEQvF2= NXG0WZJyW0GQR1XS
LAN-6 NIXUcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2fGlEPTB;MUGuPVkzQCEQvF2= MmrSV2FPT0WU
SW1573 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn1WpZvUUN3ME2xNk4{ODh4IN88US=> MmPhV2FPT0WU
NMC-G1 NGO1eoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF{LkSxO|Uh|ryP NWLmd3NjW0GQR1XS
SHP-77 M3LROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF{LkW1O|Qh|ryP M4LWfHNCVkeHUh?=
IGROV-1 M1TPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon5TWM2OD1zMj62OVc{KM7:TR?= M2[0VHNCVkeHUh?=
22RV1 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF{LkiwOVkh|ryP NIjTVYFUSU6JRWK=
SK-MEL-3 NH;jbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\JTWM2OD1zMz6zPVc{KM7:TR?= M4TBcXNCVkeHUh?=
NCI-H1563 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rlbmlEPTB;MUOuOFIxOiEQvF2= NWC5TJpqW0GQR1XS
IGR-1 NXfP[3g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPrTWM2OD1zND6wN|Q4KM7:TR?= NGr5bJNUSU6JRWK=
EW-3 NGfw[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPD[Xc5UUN3ME2xOE4yPjN7IN88US=> MoDkV2FPT0WU
JEG-3 M2ezW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7KW5NKSzVyPUG0MlQ6PTNizszN MknMV2FPT0WU
ES3 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF2Lk[1OlIh|ryP M1;DeHNCVkeHUh?=
MDA-MB-175-VII NWTUN3lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF2LkexNVEh|ryP MVXTRW5ITVJ?
P30-OHK NH7nV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnyTWM2OD1zNT6wOFk3KM7:TR?= MUTTRW5ITVJ?
GP5d NWLpOlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF3LkG0OlYh|ryP Mn3MV2FPT0WU
HMV-II MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnWTWM2OD1zNT6zN|M{KM7:TR?= MnjsV2FPT0WU
COLO-679 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF3LkWwNUDPxE1? NYHvV5hxW0GQR1XS
JAR NVvCWmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF3LkeyNFUh|ryP NVO0TVhDW0GQR1XS
NCI-H1666 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjhfmZKSzVyPUG1Mlk{QTlizszN NFLRc4pUSU6JRWK=
SW48 NYnFNIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF3Lkm1NVYh|ryP M1P6[nNCVkeHUh?=
NCI-H720 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGxcW9KSzVyPUG1Mlk6QDlizszN NXnydndIW0GQR1XS
HT-1197 NGDab2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLpc4pPUUN3ME2xOk4xOzV{IN88US=> MofIV2FPT0WU
HL-60 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jFNGlEPTB;MU[uNFM5PCEQvF2= NY[5VowxW0GQR1XS
BEN MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrITWM2OD1zNj61OlM5KM7:TR?= NWraeFA4W0GQR1XS
HAL-01 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\CRo9wUUN3ME2xOk45QTB7IN88US=> NYLXeXFzW0GQR1XS
SW900 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHaTWM2OD1zNj65NVMzKM7:TR?= NFfTbZlUSU6JRWK=
SBC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nGdGlEPTB;MUeuOVQzQSEQvF2= M1X0PXNCVkeHUh?=
SH-4 M3\KZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWwPXNKSzVyPUG3MlU5PDFizszN M3m5eXNCVkeHUh?=
UACC-62 NVi3UWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojCTWM2OD1zNz63OlM4KM7:TR?= NH\GcotUSU6JRWK=
BHT-101 NF3LXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLnTpJKSzVyPUG5Mlg4ODVizszN MXnTRW5ITVJ?
DB NYq1WJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\hV2lEPTB;MkGuOVY1QSEQvF2= M4TWUnNCVkeHUh?=
SK-MEL-1 NVLSXXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJzLkW4O|Ih|ryP NFjiem9USU6JRWK=
NCI-H747 M1fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3RVGNKSzVyPUKyMlc{PzlizszN NWnTPG9XW0GQR1XS
SK-LU-1 M3m3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULTVotZUUN3ME2yN{4{PTJ2IN88US=> NGCyNFVUSU6JRWK=
KG-1 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fMdWlEPTB;MkOuOFk1PiEQvF2= MlrEV2FPT0WU
LXF-289 NVvVSpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zydGlEPTB;MkOuO|E1KM7:TR?= MWfTRW5ITVJ?
HCC1954 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O4dmlEPTB;MkSuPFg1PCEQvF2= M3[xV3NCVkeHUh?=
Ramos-2G6-4C10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHVTWM2OD1{Nj60PVgyKM7:TR?= Mly3V2FPT0WU
DBTRG-05MG NGD6dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ4Lk[0PFgh|ryP NX63RnBYW0GQR1XS
NCI-H2052 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f4UmlEPTB;MkeuOVY5PCEQvF2= MojuV2FPT0WU
RMG-I NXL2ZYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjqRo9KSzVyPUK5MlQyOzlizszN MYLTRW5ITVJ?
H9 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNzLkOwNFgh|ryP M3;CTHNCVkeHUh?=
GR-ST Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonBTWM2OD1|Mj60OFU{KM7:TR?= MWTTRW5ITVJ?
Mo-T NXPTO5V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\STWM2OD1|Mj61NFQ3KM7:TR?= Ml7CV2FPT0WU
SW1088 NXvVN2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT5UYVSUUN3ME2zNk46QDBzIN88US=> MY\TRW5ITVJ?
LB2518-MEL M4riT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\IT2RKSzVyPUOzMlA4QTdizszN MmfXV2FPT0WU
NCI-H82 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPaNGxKSzVyPUOzMlE3PjFizszN MWLTRW5ITVJ?
LAMA-84 NHTOTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz2TWM2OD1|ND62NFc{KM7:TR?= NEX1UWZUSU6JRWK=
KYSE-450 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUewOGJIUUN3ME2zOE43Pzd4IN88US=> M4PK[XNCVkeHUh?=
LU-99A M4jZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDOSlhKSzVyPUO1MlAxODdizszN M1HWTXNCVkeHUh?=
BE-13 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml76TWM2OD1|NT62OVQ2KM7:TR?= MmnLV2FPT0WU
GAK MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN3Lk[5OUDPxE1? MmP3V2FPT0WU
NCI-H1573 M17qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\oUWNKSzVyPUO1Mlg5OThizszN Mn;BV2FPT0WU
AsPC-1 NH\XNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfvTWM2OD1|Nj6xOVI4KM7:TR?= M17RXXNCVkeHUh?=
HDLM-2 NHfJR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPxO5BKSzVyPUO2MlMyPiEQvF2= M3nE[3NCVkeHUh?=
NCI-H441 NVrMdotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HVd2lEPTB;M{euNFY6OSEQvF2= MW\TRW5ITVJ?
CAL-27 M4Hyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\mPVkyUUN3ME2zO{44OjNzIN88US=> M2fWWnNCVkeHUh?=
OVCAR-3 NUmx[ZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\VXmlEPTB;M{muN|E5OSEQvF2= M37JVnNCVkeHUh?=
RPMI-8226 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17tSmlEPTB;M{muOVk5KM7:TR?= NU\rNphUW0GQR1XS
EFO-21 NGjlO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrYT3BKSzVyPUSwMlU5OTRizszN Mn7sV2FPT0WU
SNU-C2B M4TOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRzLkWwPFQh|ryP NGXWbY9USU6JRWK=
VM-CUB-1 NWG4[lJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHSd4xDUUN3ME20N{45ODN5IN88US=> Mn\VV2FPT0WU
NCI-H2087 M3XlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPG[ZlKSzVyPUS1MlAzOzNizszN MlzvV2FPT0WU
EW-16 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\wTWM2OD12Nj6zNVM4KM7:TR?= MWrTRW5ITVJ?
SK-N-AS M13NVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPCfllKSzVyPUS2MlcyPjdizszN M3rhRXNCVkeHUh?=
COR-L105 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTR4Lki4OVch|ryP M4LQT3NCVkeHUh?=
DEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXJXpJrUUN3ME20PE4xPDJ7IN88US=> NH;UV5RUSU6JRWK=
JVM-2 NWnGTox1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR6LkC1OVgh|ryP MUHTRW5ITVJ?
KARPAS-45 NFPWT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHMTWM2OD12OT60OVM5KM7:TR?= NHXCSVZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID